Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (twice daily) vs placebo
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes onlyno estimate extracted1 study · 204 participantsLow